🔗 Share this article

While America continues making sweeping revisions to its immunization schedules, one figure has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about Covid vaccinations in the pandemic and has concentrated on alleged fatalities after COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Schedule

Public health authorities planned to announce sweeping changes to the pediatric vaccine schedule recently, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would put the US out of alignment with many the world with little proof for benefit. This reveal has been pushed back until the new year.

In place of the top vaccines chief, Dr. Høeg is listed to present at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to run the center this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon reevaluating previously authorized vaccines at the FDA.

The new acting director has often pushed for ending specific childhood vaccine recommendations in the US in order to be more in line with Denmark's approach, a society with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – usually the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible experience in pharmaceutical research, approval processes or leadership, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“She doesn’t seem to have the necessary background” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Past commissioners of CBER would “understand laws and regulations and the science of medication creation”, commented Janet Woodcock. “Frankly, she has not acquired the type of experience that former directors who ran the center have had.”

The drug center has an vast workload at the FDA, Woodcock emphasized.

“Everybody just focuses on the innovative therapies, but the generic drug division approves numerous generic medications. There is also a biosimilars program, over-the-counter program and other areas, and every single one need to be supervised,” Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant administrative element to the job, which supervises in excess of 5,000 staff members. “It is a massive management job, if you do it right,” the former official added.

Official Statement and Contentious Programs

In response to concerns about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a representative stated that the “inquiries are based on inaccurate presumptions”.

“Her resume is consistent with the duties of her role,” the official explained, pointing to the months Dr. Høeg spent advising the agency head on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a controversial one-day drug-approval program that reportedly concerned her former heads. “By what process are these drugs being picked for this expedited pathway? Who takes the decisions?” Dr. Howard said. “There is a lot of confidentiality occurring at the agency right now.”

In general, he stated, “the agency appears to be shifting towards more relaxed rules of most medications, except for shots.”

Public History on Immunizations

With vaccines, Høeg has a clearer, if concerning, past, critics have noted. She published a research paper using non-validated volunteer-provided data to estimate the frequency of heart inflammation after Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are riskier than they are.

Included in her “policy goals” for the new administration encompassed changing guidelines for recently developed shots and discontinuing “optional” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of barring teenage boys from getting Covid vaccinations.

“She is an complete true believer who begins with her preconceived notions and reverse-engineers to accommodate the data in a extremely deceptive, fraudulent manner,” Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg became part of fellow dissenters, {like|